Oncology News | pharmaphorum

News

Then there were two: ArriVent set to list after $175m IPO

ArriVent BioPharma was beaten to the first biotech initial public offering of the year when CG Oncology made its debut on the Nasdaq yesterday, but is due to start trading

News

Synnovation’s $102m round heads latest biotech financings

Momentum seems to be building behind biotech financings as the first month of 2023 draws to a close, with a respectable raise for cancer start-up Synnovation Therapeutics

News

Glenmark licenses cancer drug from China’s Alphamab, 3D Med

India’s Glenmark Pharma has added to its oncology pipeline by licensing rights to a checkpoint inhibitor from China’s Jiangsu Alphamab Biopharmaceuticals and 3D Medicines

News

Next stage in GSK’s Zantac defense gets underway today

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients.

News

Trial data raises questions about Imfinzi in liver cancer

AstraZeneca is trying to blaze a new trial for immunotherapy in liver cancer with its EMERALD-1 trial, but the jury is out on its prospects.

News

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

The combination of Bristol-Myers Squibb’s Opdivo and Yervoy cancer immunotherapies is on track for approval as a first-line therapy for patients with a particular form of

Then there were two: ArriVent set to list after $175m IPO

Synnovation’s $102m round heads latest biotech financings

Glenmark licenses cancer drug from China’s Alphamab, 3D Med

Next stage in GSK’s Zantac defense gets underway today

Trial data raises questions about Imfinzi in liver cancer

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks